What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Reference-code fill; Tirzepatide identity verified per batch COA · 60 mg
Overview
GLP1-T-60 is the largest fill in the Tirzepatide-class reference-code family at 60 mg lyophilized per vial. The fill size targets distributor workflows that require larger-than-standard per-vial quantities for fractionation into smaller dispensing presentations or for direct use in higher-dose research and compounding protocols. The 'T' code designation indicates Tirzepatide GIP/GLP-1 dual agonist material per the upstream supplier price-table convention; identity confirmation against the released batch COA is essential at order time. For direct procurement, the named Tirzepatide SKU with its broader 12-fill-size flexibility (2 mg through 120 mg) is generally the cleaner procurement route. Distributor buyers fractionating the T-60 fill into smaller downstream presentations should plan the fractionation workflow under sterile or near-sterile conditions: lyophilized peptide is exposed to ambient air during the fill-split step and any contamination introduced at that point compromises the subsequent fills. PeptideXpo offers optional pre-fractionation OEM service that splits the T-60 batch into smaller standardized fills under ISO 7/8 cleanroom conditions, eliminating the in-house sterile-fill burden for the buyer.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: regional distributors and re-sellers.
Specifications
Documentation available on request
Regulatory note
Reference code; verify API identity via batch-specific COA before order placement.
Frequently asked questions
GLP1-T-60 at 60 mg lyophilized per vial targets two specific workflows: (1) distributor buyers who plan to fractionate the larger batch into smaller dispensing-fill sizes under their own ISO-compliant cleanroom conditions, and (2) buyers in high-volume research or compounding contexts where the per-vial overhead amortization at 60 mg meaningfully improves cost economics versus repeated smaller orders. For buyers without in-house sterile-fill capability, PeptideXpo can pre-fractionate the T-60 batch into smaller standardized fills under ISO 7/8 cleanroom conditions as part of the OEM service, eliminating the post-purchase sterile-fill burden.
Fractionating a 60 mg lyophilized bulk vial into smaller standardized fills requires: (1) controlled-environment reconstitution of the bulk lyophilizate in a clean diluent (typically Water for Injection), (2) sterile-filtration of the reconstituted solution through 0.22 μm filters into a sterile holding vessel, (3) controlled-aliquot fill of the filtered solution into individual smaller vials under ISO 7/8 cleanroom conditions, and (4) terminal re-lyophilization in the smaller vials to produce the final dispensing format. Each step requires the buyer to have appropriate facility infrastructure and validated procedures. PeptideXpo's pre-fractionation OEM service eliminates the need for the buyer to maintain this infrastructure, particularly useful for distributors who don't operate their own sterile-fill facilities.
The pre-fractionation workflow runs through PeptideXpo's ISO 7/8 cleanroom facility: the bulk T-60 batch is reconstituted, sterile-filtered, aliquoted into the buyer's specified smaller-fill format (typically 5 mg, 10 mg, or 15 mg per smaller vial), and terminal-lyophilized. The released-batch documentation covers both the original bulk-vial QC (HPLC, mass spec, water content) and the smaller-vial release testing (sterility per USP <71>, container-closure integrity, fill-weight verification). Lead time adds approximately 1 week to the standard 14-21 day production schedule. Pricing is configured per smaller-vial output rather than per bulk T-60 input. Discuss the target fill size and quantity at quote stage to receive specific pricing.
Related peptides
GIP / GLP-1 dual receptor agonist
Reference-code fill; Tirzepatide identity verified per batch COA · 10 mg
Reference-code fill; Tirzepatide identity verified per batch COA · 30 mg
